摘要
目的观察三氧化二砷(As2O3)-碘化油乳剂经肝动脉化疗栓塞(TACE)治疗原发性肝细胞癌(PHC)的临床疗效。方法PHC患者145例,根据碘化油所用乳化药物不同分为三组:As2O3+碘化油组(A组)47例、阿霉素+碘化油组(B组)48例和单纯碘化油组(C组)50例。首次TACE治疗后4~6周再行第2次TACE治疗。随访1年以上,观察临床疗效及不良反应。结果A、B、C组的近期临床有效率分别为59.6%、41.7%、40.0%,疾病控制率分别为93.6%、79.2%、72.0%,中位生存期分别为30、26、25个月。A组近期临床有效率、疾病控制率及中位生存期均优于B、C组(P<0.05)。三组TACE术后主要不良反应为恶心、呕吐、肝区疼痛、发热、骨髓抑制及肝功能受损等,经对症处理后均缓解或消失。结论 As2O3-碘化油乳剂TACE治疗PHC的临床疗效确切,不良反应可耐受。
Objective To observe the clinical efficacy of transarterial chemoembolization（TACE）with arsenic trioxide（As_2O_3）-lipiodol emulsion in treating the patients with primary hepatocellular carcinoma（PHC）.Methods A total of 145 PHC patients was randomly divided into three groups of A（treated with As_2O_3 ＋lipiodol,47cases）,B（treated with doxorubicin＋lipiodol,48cases）and C（treated with lipiodol alone,50cases）.The second treatment of TACE was performed after 4-6weeks of the first TACE treatment.The patients were followed up for over one year.Clinical efficacy and adverse effects were compared among three groups.Results The short-term clinical response rate,disease control rate and median survival period in group A were 59.6%,93.6% and 30 months,respectively,which were better than those in groups of B（41.7%,79.2%and 26months）and C（40.0%,72.0% and 25months）（P〈0.05）.The major adverse effects of three groups were nausea,vomiting,hepatalgia,fever,myelosuppression and liver dysfunction,which were attenuated or disappeared after symptomatic treatments.Conclusion For treating the patients with PHC,TACE with As2O3-lipiodol emulsion is definitely effective with tolerable adverse effects.
出处
《江苏医药》
CAS
2017年第5期321-325,共5页
Jiangsu Medical Journal
关键词
原发性肝细胞癌
三氧化二砷
肝动脉化疗栓塞
Primary hepatocellular carcinoma
Arsenic trioxide
Transarterial chemoembolization
